Levacetylleucine PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1188-21-2
Molecular formula
C8H15NO3
Molecular weight
173.21 g/mol
Drug class
Acetylated L-leucineneurometabolic therapy for selected inherited neurological disorders
Mechanism of action
The mechanism is not fully established. Acetylated leucine may modulate neuronal energy metabolism, membrane stability and cerebellar network function; no single molecular target is confirmed as the clinical mechanism.
Indications / reported uses
Treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients weighing at least 15 kg under the US AQNEURSA indication
Treatment of ataxia-telangiectasia in adults and paediatric patients weighing at least 15 kg under the US indication where authorised; verify current label wording for disease-specific use
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Levacetylleucine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levacetylleucine Permitted Daily Exposure (PDE) report (the Levacetylleucine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levacetylleucine Occupational Exposure Limit (OEL) report (the Levacetylleucine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.